ALXN 1210

Drug Profile

ALXN 1210

Alternative Names: ALXN1210

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Alexion Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Phase I Immunological disorders

Most Recent Events

  • 06 Jan 2017 Alexion Pharmaceuticals has patent protection for ALXN 1210 in USA and Europe
  • 06 Jan 2017 ALXN 1210 receives Orphan Drug status for Paroxysmal nocturnal haemoglobinuria in USA
  • 04 Dec 2016 Interim pharmacodynamics and safety data from a phase I/II trial in Paroxysmal nocturnal haemoglobinuria presented at the 58th American Society of Hematology annual meeting (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top